Background: Corticobasal syndrome (CBS) has a heterogeneous neuropathological spectrum, ranging from the classical corticobasal degeneration to Alzheimer's disease (AD). The neuropathology of CBS is still unpredictable. CSF tau/abeta ratio is a reliable marker of AD.
Objective: To evaluate the presence of a distinct clinical and neuroimaging CBS phenotype according to CSF pattern.
Methods: 30 patients fulfilling current clinical criteria for CBS entered the study. Each patient underwent a clinical and standardised neuropsychological assessment, and CSF analysis (total tau and abeta42 dosages). CSF AD-like pattern and CSF non-AD like pattern (nAD-like) were identified. In 23 CBS cases, (99m)Tc-ECD single photon emission computed tomography (SPECT) scan was performed and analysed by statistical parametric mapping.
Results: CSF AD-like pattern was reported in six cases (20%). The two subgroups did not differ in demographic characteristics or global cognitive impairment. The AD-like group showed greater impairment of memory performances, language and psychomotor speed while the nAD-like group had more severe extrapyramidal syndrome with comparable apraxia scores. Voxel by voxel analysis on SPECT images demonstrated that CBS AD-like patients had greater hypoperfusion in the brain areas typically affected by AD-namely, precuneus, posterior cingulate and hippocampus, bilaterally-compared with nAD-like patients (p<0.001). No clusters above the pre-established threshold were detected when nAD-like were compared with AD-like patients.
Conclusions: CSF AD-like profile in CBS is associated with earlier memory impairment and brain abnormalities typically found in classical AD. These findings argue for the usefulness of CSF testing to identify AD in CBS, and might suggest a different pharmacological approach on the basis of biological data.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/jnnp.2010.221853 | DOI Listing |
J Neuropsychiatry Clin Neurosci
January 2025
Departments of Psychiatry (Rivas-Grajales) and Neurology (Han, Wang), Boston University Chobanian & Avedisian School of Medicine, Boston; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (Greenstein, Shih).
Alzheimers Dement
December 2024
Università degli studi di Genova, Genova, Liguria, Italy
Background: Alzheimer's disease (AD) is the most common form of dementia, predominantly manifesting as amnestic impairment. However, atypical presentations such as logopenic variant of primary progressive aphasia (lvPPA), posterior cortical atrophy (PCA), corticobasal syndrome (CBS) and frontal AD pose diagnostic challenges. This study presents preliminary data from a retrospective analysis investigating brain functional differences between typical and atypical AD forms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Mayo Clinic, Rochester, MN, USA
Background: Corticobasal syndrome (CBS) is a progressive neurodegenerative syndrome that can result from several underlying neuropathologies, including Alzheimer’s disease (AD). Little is known about the utility of blood plasma measures to predict PET biomarker confirmed AD in CBS.
Method: Eighteen CBS patients (8 PET Aβ+; 10 PET Aβ‐) and 8 cognitively unimpaired Aβ‐ individuals (CU) were recruited by the Neurodegenerative Research group from the Department of Neurology, Mayo Clinic, Rochester, MN, underwent Aβ (Pittsburgh Compound‐B) and tau (F‐flortaucipir) PET and provided a blood sample.
Alzheimers Dement
December 2024
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands
Background: There is a strong link between tau and progression of Alzheimer’s disease (AD), necessitating an understanding of tau spreading mechanisms. Prior research, predominantly in typical AD, suggested that tau propagates from epicenters (regions with earliest tau) to functionally connected regions. However, given the constrained spatial heterogeneity of tau in typical AD, validating this connectivity‐based tau spreading model in AD variants with distinct tau deposition patterns is crucial.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
Background: Diagnosing sporadic early‐onset AD (EOAD, age‐at‐onset<65) is challenging: in the multi‐center Longitudinal Early‐onset Alzheimer’s Disease Study, ∼25% of patients with clinically diagnosed EOAD are amyloid‐PET‐negative. Here we used FDG‐PET to characterize the heterogeneity of hypometabolic profiles in these patients and better identify underlying etiologies.
Method: Seventy‐four amyloid‐PET‐negative patients with clinical diagnosis of sporadic EOAD (MCI or mild dementia stage) underwent FDG‐PET.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!